Autoimmune diseases afflict nearly 1 in 12 Americans and many more have autoantibodies but no evidence of clinical disease. Recent work has identified biomarkers or clinical symptoms which associate with subsequent developing development of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and NIH-funded prevention trials are underway. AoU provides a unique opportunity to identify at risk individuals through surveys and blood tests, and to identify molecular pathways of disease.
Idea No. 816